Cystic Fibrosis Foundation Therapeutics, Inc.

Cystic Fibrosis Foundation

Pfizer Corporation

Rajiah Aldrin Denny

Joseph Walter Strohbach

John Paul Mathias

Atli Thorarensen

Christoph Wolfgang Zapf

David Christopher Limburg

Ivan Viktorovich Efremov

John James Mousseau

Lori Krim Gavrin

Daniel Elbaum

Jennifer Elizabeth Davoren

Scott William Bagley

John Isidro Trujillo

Frank Eldridge Lovering

Brian Stephen Gerstenberger

Agustin Casimiro-Garcia

Mihir D Parikh

James John Mousseau

Xiayun Cheng

The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein Rto Rare as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.

Benzimidazole derivative compounds and uses thereof

The present invention relates to 5,7-disubstituted-imidazo[5,1-f][1,2,4]triazine-4-amine derivatives, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compounds, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sj&#xf6;gren's Syndrome, and other CFTR associated disorders.

Bicyclic heteroaryl derivatives as CFTR potentiators

The present invention relates to methods of using compounds of Formula I, 

Pyrrolopyrimidines as CFTR potentiators

The present invention relates to compounds of Formula I, 

The present invention relates to 1,3-disubstituted-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compounds, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sj&#xf6;gren's Syndrome, and other CFTR associated disorders.

The present invention relates to 1,3-disubstituted-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives, 5,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives or 5,7-disubstituted-imidazo[5,1-f][1,2,4]triazine-4-amine derivatives, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compounds, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sj&#xf6;gren's Syndrome, and other CFTR associated disorders.

Growing community of inventors

Sharon, MA, United States of America

Rajiah Aldrin Denny